§ Federal grant opportunity · HT942526DMDRPCTRA
DoW Duchenne Muscular Dystrophy, Clinical/Translational Research Award
Danielle Reckley Grantor is accepting applications for DoW Duchenne Muscular Dystrophy, Clinical/Translational Research Award. The deadline is September 18, 2026 and the published award range is Award amount not published.
Key facts
- Funder
- Danielle Reckley Grantor
- Application deadline
- September 18, 2026
- Award range
- Award amount not published
- Eligibility
- Eligibility criteria are published in the funding opportunity announcement.
- Geography
- United States
- Focus areas
- Research
- Opportunity number
- HT942526DMDRPCTRA
Program overview
Summary: The fiscal year 2026 (FY26) Duchenne Muscular Dystrophy Research Program (DMDRP) Clinical/Translational Research Award (CTRA) supports advanced translational research to accelerate promising ideas in Duchenne muscular dystrophy (DMD) research toward clinical applications. Research must address at least one of the FY26 CTRA Focus Areas. Research projects investigating therapies that will be efficacious across the life span are strongly encouraged. Distinctive Features: The FY26 CTRA offers two funding levels: • Funding Level 1 to support smaller, less complex preclinical and/or clinical research. • Funding Level 2 to support larger, more complex preclinical and/or clinical research. The FY26 CTRA also offers a Partnering PI Option (PPIO) to support meaningful and productive partnerships between two investigators collaborating on the proposed research project. The PPIO has two eligibility categories: • Early-Career Partnering PI category for an independent, early-career investigator within 10 years of their first faculty appointment (or equivalent) by the time of application submission. • Established Interdisciplinary Partnering PI for independent investigators at all academic levels, or equivalent, in an area other than muscular dystrophy, seeking to transition to a career in DMD, thereby bringing their expertise to the field. Preliminary data are required for all applications. Pilot clinical trials and clinical trial readiness studies to better inform development of drugs, devices, and other interventions are allowed.
How to apply
- Confirm your organization meets the eligibility criteria above.
- Read the full funding opportunity announcement from Danielle Reckley Grantor.
- Draft your narrative against the funder's stated priorities and review criteria.
- Submit before September 18, 2026, allowing time for registration and validation.
Related grant opportunities
- DoW Duchenne Muscular Dystrophy, Idea Development Award
- F26AS00051_FY 2026 Competitive State Wildlife Grant (C-SWG) Program_Funding Opportunity Announcement
- National Estuarine Research Reserve System (NERRS) Land Acquisition and Construction Program for Fiscal Year 2026
- NRCS' Feral Swine Eradication and Control Pilot Program Fiscal Year (FY) 2026
- Plant Protection Act Section 7721 Plant Pest and Disease Management and Disaster Prevention Program (PPDMDPP)
Find every grant your organization qualifies for
Mavenly scores this opportunity against your mission, geography, and funding history — then drafts the proposal with you and tracks the deadline through submission and reporting.